CLINICAL TRIALS PROFILE FOR VIVACAINE

« Back to Dashboard

All Clinical Trials for VIVACAINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00915473 ↗	Greater Occipital Nerve Block for Migraine Prophylaxis	Completed	National Center for Advancing Translational Science (NCATS)	Phase 4	2009-06-01	Migraine is a common neurological condition that can be disabling, particularly if chronic. Greater occipital nerve (GON) block has been utilized for decades for the treatment of migraine in the absence of a single randomized, placebo-controlled trial documenting its effectiveness. Hypothesis: Greater occipital nerve block reduces the frequency of days with moderate or severe headache in patients with episodic or chronic migraine.
NCT00915473 ↗	Greater Occipital Nerve Block for Migraine Prophylaxis	Completed	Mayo Clinic	Phase 4	2009-06-01	Migraine is a common neurological condition that can be disabling, particularly if chronic. Greater occipital nerve (GON) block has been utilized for decades for the treatment of migraine in the absence of a single randomized, placebo-controlled trial documenting its effectiveness. Hypothesis: Greater occipital nerve block reduces the frequency of days with moderate or severe headache in patients with episodic or chronic migraine.
NCT01906944 ↗	Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain	Completed	Mayo Clinic	Phase 2	2012-01-01	Patients with chronic abdominal pain- with a component of abdominal wall pain- are often treated with trigger point injections. This study will help to determine if a block within the transversus abdominis plane (TAP) will provide superior analgesic benefit to a trigger point injection as therapy for these patients.
NCT03749408 ↗	Effect of Addition of Mannitol to Bupivacaine on IANB Success and Post-endodontic Pain	Completed	Cairo University	Phase 2/Phase 3	2012-12-01	Inferior alveolar nerve block using either 0.5% bupivacaine alone or in addittion to mannitol in patients with irreversible pulpitis in mandibular molars.

Clinical Trial Conditions for VIVACAINE

Condition Name

Condition Name for VIVACAINE
Intervention	Trials
Abdominal Pain	1
Irreversible Pulpitis	1
Migraine Headache	1

Condition MeSH

Condition MeSH for VIVACAINE
Intervention	Trials
Pulpitis	1
Abdominal Pain	1
Migraine Disorders	1
Headache	1

Clinical Trial Locations for VIVACAINE

Trials by Country

Trials by Country for VIVACAINE
Location	Trials
United States	2

Trials by US State

Trials by US State for VIVACAINE
Location	Trials
Minnesota	1
Arizona	1

Clinical Trial Progress for VIVACAINE

Clinical Trial Phase

Clinical Trial Phase for VIVACAINE
Clinical Trial Phase	Trials
Phase 4	1
Phase 2/Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for VIVACAINE
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for VIVACAINE

Sponsor Name

Sponsor Name for VIVACAINE
Sponsor	Trials
Mayo Clinic	2
National Center for Advancing Translational Science (NCATS)	1
Cairo University	1

Sponsor Type

Sponsor Type for VIVACAINE
Sponsor	Trials
Other	3
NIH	1

Last updated: May 21, 2026

VIVACAINE (Bupivacaine) Clinical Trials Update, Market Analysis, and Exclusivity Projection

Executive summary: VIVACAINE is a brand of bupivacaine hydrochloride used as a local anesthetic for regional anesthesia and pain control. Public clinical-trial visibility and patent/IP granularity at the “VIVACAINE” brand level are limited in open sources because bupivacaine products are widely authorized under multiple strengths, formulations, and label variants. Market outlook is therefore driven primarily by (1) total class demand for long-acting amide local anesthetics, (2) substitution among bupivacaine generics and competing brands, and (3) how long-acting formulations with specific label indications hold share against cheaper generic equivalents.

No complete, reliable dataset is available in the provided context to produce an accurate “clinical trials update” (trial IDs, statuses, endpoints, and sponsors) and an evidence-grade “exclusivity projection” (FDA exclusivity and Orange Book patent-by-patent expiration schedule for the specific VIVACAINE listed product).